Point72 Asset Management Fully Exits Position in Forte Biosciences, Inc. (FBRX)

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have filed an amendment to their Schedule 13G regarding Forte Biosciences, Inc. (FBRX). The filing, dated May 15, 2026, and reflecting an event date of March 31, 2026, reports that the reporting persons have completely exited their position in the company's common stock. As of the reporting date, the filers beneficially own 0 shares, representing 0.0% of the outstanding common stock. This is an amendment to a previous filing and indicates that the reporting persons have ceased to be beneficial owners of more than five percent of the class of securities. The entities involved include Point72 Asset Management, a Delaware limited partnership, and Point72 Capital Advisors, Inc., a Delaware corporation, both controlled by Steven A. Cohen. The filing was made under Rule 13d-1(c), indicating a passive investment intent at the time of holding. All voting and dispositive powers are now reported as zero across all reporting persons.